• 
  T. Aparicio, O. Bouché, P. L. Etienne, E. Barbier, L. Mineur, et al.. Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial. Digestive and Liver Disease, 2022, pp.S1590-8658(22)00662-4. ⟨10.1016/j.dld.2022.08.036⟩. ⟨inserm-03986083⟩
• 
  François Quénet, Dominique Elias, Lise Roca, Diane Goéré, Laurent Ghouti, et al.. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 2021, 22 (2), pp.256-266. ⟨10.1016/s1470-2045(20)30599-4⟩. ⟨hal-03220825⟩
• 
  Coline Montégut, Jean-Sébastien Guillamo, François Ducray, Caroline Dehais, Elisabeth Cohen-Jonathan Moyal, et al.. Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study. Cancers, 2022, 14 (22), pp.5509. ⟨10.3390/cancers14225509⟩. ⟨hal-03881443v2⟩
• 
  Roseline Vibert, Khadija Lahlou-Laforêt, Maryam Samadi, Valérie Krivosic, Thomas Blanc, et al.. Minors at risk of von Hippel-Lindau disease: 10 years’ experience of predictive genetic testing and follow-up adherence. European Journal of Human Genetics, 2022, 30 (10), pp.1171-1177. ⟨10.1038/s41431-022-01157-z⟩. ⟨inserm-03940490⟩
• 
  Julien Edeline, Tim Meyer, Jean-Frédéric Blanc, Jean-Luc Raoul. New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations. Cancers, 2022, 14 (23), pp.5868. ⟨10.3390/cancers14235868⟩. ⟨hal-03924755⟩
• 
  Emmanuelle Samalin, Christelle de La Fouchardière, Simon Thèzenas, Valérie Boige, Hélène Senellart, et al.. Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). Clinical Colorectal Cancer, 2020, ⟨10.1016/j.clcc.2020.04.008⟩. ⟨hal-02912931⟩
• 
  Luc Ollivier, Charles Orione, Paul Bore, Laurent Misery, Delphine Legoupil, et al.. Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study. Cancers, 2022, 14 (17), pp.4213. ⟨10.3390/cancers14174213⟩. ⟨inserm-03878079⟩
• 
  M. Debaudringhien, Jean-Yves Blay, André-Michel Bimbai, Sylvie Bonvalot, Antoine Italiano, et al.. Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis. ESMO Open, 2022, 7 (5), pp.100578. ⟨10.1016/j.esmoop.2022.100578⟩. ⟨hal-03837188⟩
• 
  Ke Zhou, Martine Bellanger, Sophie Le Lann, Marie Robert, Jean-Sebastien Frenel, et al.. The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life. Frontiers in Oncology, 2022, 12, pp.925534. ⟨10.3389/fonc.2022.925534⟩. ⟨hal-03842272⟩
• 
  Marc Peeters, David Planchard, Mark Pegram, João Gonçalves, François Bocquet, et al.. Biosimilars in an era of rising oncology treatment options. Future Oncology, 2021, 17 (29), pp.3881-3892. ⟨10.2217/fon-2021-0546⟩. ⟨hal-03635306⟩
• 
  Patrick Robelin, Michel Tod, Olivier Colomban, Joel Lachuer, Isabelle Ray-Coquard, et al.. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). Gynecologic Oncology, 2020, 159, pp.256 - 263. ⟨10.1016/j.ygyno.2020.07.021⟩. ⟨hal-03491450⟩
• 
  Jean-Baptiste Alberge, Françoise Kraeber-Bodéré, Bastien Jamet, Cyrille Touzeau, Hélène Caillon, et al.. Molecular Signature of 18 F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. Journal of Nuclear Medicine, 2022, 63 (7), pp.1008-1013. ⟨10.2967/jnumed.121.262884⟩. ⟨hal-03807107⟩
• 
  Gwennan André-Grégoire, Clément Maghe, Tiphaine Douanne, Sara Rosińska, Fiorella Spinelli, et al.. Inhibition of the pseudokinase MLKL alters extracellular vesicle release and reduces tumor growth in glioblastoma. iScience, 2022, 25, pp.105118. ⟨10.1016/j.isci.2022.105118⟩. ⟨inserm-03787564⟩
• 
  Y. Ghannam, C. Bourgier, F. Legouté, A. Gonzalez-Moya, T. Lizée, et al.. Irradiation de la tumeur primitive en cas de cancer du sein métastatique synchrone. Cancer/Radiothérapie, 2020, 24, pp.567 - 575. ⟨10.1016/j.canrad.2020.06.008⟩. ⟨hal-03492125⟩
• 
  Nadia Younan, Carole Soussain, Sylvain Choquet, Nathalie Cassoux, Valérie Touitou, et al.. Isolated intraocular relapses of primary cerebral lymphomas: An loc network study. Hematological Oncology, 2022, 40 (5), pp.976-986. ⟨10.1002/hon.3044⟩. ⟨hal-03716518⟩
• 
  Thomas L Bonneaud, Chloé Lefebvre, Lisa Nocquet, Agnes Basseville, Julie Roul, et al.. Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties. Cell Death and Disease, 2022, 13 (9), pp.787. ⟨10.1038/s41419-022-05214-9⟩. ⟨inserm-03777381⟩
• 
  F. Derquin, A. Floquet, A.C. Hardy-Bessard, J. Edeline, J.P. Lotz, et al.. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network. Gynecologic Oncology, 2020, 158 (3), pp.666-672. ⟨10.1016/j.ygyno.2020.06.491⟩. ⟨hal-02909552⟩
• 
  Paul Lesueur, Gandhi Damaj, Khê Hoang-Xuan, Virginie Roland, Anna Schmitt, et al.. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Advances, 2022, 6 (16), pp.4807 - 4815. ⟨10.1182/bloodadvances.2022007011⟩. ⟨hal-03761560⟩
• 
  Guillaume Janoray, Yoann Pointreau, Marc Alfonsi, Christian Sire, Lionel Geoffrois, et al.. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial. European Journal of Cancer, 2020, 133, pp.86 - 93. ⟨10.1016/j.ejca.2020.04.009⟩. ⟨hal-03490774⟩
• 
  Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, et al.. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncology, 2019, 20, pp.1740 - 1749. ⟨10.1016/S1470-2045(19)30486-3⟩. ⟨hal-03489049⟩

182

266